Trigemina Presented at American Headache Society 56th Annual Scientific Meeting
July 01, 2014 09:00 ET
|
Trigemina
MORAGA, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products,...
Trigemina Announces Expansion of Phase II Study of TI-001 for Chronic Migraine
February 06, 2014 09:43 ET
|
Trigemina
MORAGA, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products,...
Trigemina to Present Nasal Oxytocin Data at Pain Therapeutics Summit East
September 25, 2013 08:05 ET
|
Trigemina
MORAGA, Calif., Sept. 25, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products,...
Trigemina Presents Data on Intranasal Oxytocin for the Treatment of Trigeminal Neuralgia
August 29, 2013 12:19 ET
|
Trigemina
MORAGA, Calif., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products,...
Trigemina to Present at the 2013 International Headache Congress
June 26, 2013 08:07 ET
|
Trigemina
BOSTON, June 26, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, will be...
Trigemina Attracts $4.5 Million Funding From Current Investors and Chilean Government Grant
June 17, 2013 08:07 ET
|
Trigemina
MORAGA, Calif., June 17, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products,...
Trigemina Initiates Phase II Clinical Trial of TI-001 for Chronic Migraine
June 10, 2013 09:01 ET
|
Trigemina
SANTIAGO, Chile, June 10, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products,...